Kamada Ltd. (TASE: KMDA) has obtained marketing approval by Russia's Ministry of Health for the company's intravenous AAT (Alpha-1 Antitrypsin) drug for congenital respiratory diseases. The drug will be marketed under the name "RespiKam".
Earlier this month, the US Food and Drug Administration (FDA) awarded the commercial name "Glassia" for the intravenous AAT drug, and Kamada is waiting for FDA marketing approval for the drug, which it expects in July. Kamada is also pursuing efforts to register, market, and sell the drug in other countries around the world.
Kamada CEO David Tsur said, "This is another vote of confidence in the company and in the medication. We recently obtained marketing approval for the drug in Brazil, and began sales there this year."
Kamada's share price rose 6.3% by midday to NIS 19.54, giving a market cap of NIS 504 million.
Published by Globes [online], Israel business news - www.globes-online.com - on May 26, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010